Harmony Biosciences Holdings (HRMY) Common Equity (2019 - 2026)

Harmony Biosciences Holdings (HRMY) has 8 years of Common Equity data on file, last reported at $910.3 million in Q1 2026.

• For the quarter ending Q1 2026, Common Equity rose 26.35% year-over-year to $910.3 million; the trailing twelve-month figure through Mar 2026 stood at $910.3 million (up 26.35% YoY), and the FY2025 full-year result was $870.2 million, up 32.02% from the prior year.
• Common Equity climbed to $910.3 million in Q1 2026, from $870.2 million in the prior quarter.
• In the past five years, Common Equity ranged from a high of $910.3 million in Q1 2026 to a low of $214.5 million in Q1 2022.
• A 5-year average of $559.0 million and a median of $515.4 million in 2024 frame the typical range for Common Equity.
• Across the five-year window, Common Equity surged 126.21% in 2022 and increased 11.01% in 2024, its largest moves.
• Tracing HRMY's Common Equity over 5 years: stood at $402.8 million in 2022, then grew by 15.93% to $467.0 million in 2023, then soared by 41.15% to $659.2 million in 2024, then surged by 32.02% to $870.2 million in 2025, then grew by 4.61% to $910.3 million in 2026.
• Business Quant data shows HRMY's Common Equity at $910.3 million in Q1 2026, $870.2 million in Q4 2025, and $835.1 million in Q3 2025.